Francesco Tromby, Valeria Manfrè, Loukas G Chatzis, Suzanne Arends, Athanasios G Tzioufas, Hendrika Bootsma, Luca Quartuccio, Elena Bartoloni
{"title":"Clinical manifestations, imaging and treatment of Sjögren's disease: one year in review 2024.","authors":"Francesco Tromby, Valeria Manfrè, Loukas G Chatzis, Suzanne Arends, Athanasios G Tzioufas, Hendrika Bootsma, Luca Quartuccio, Elena Bartoloni","doi":"10.55563/clinexprheumatol/5xq3fb","DOIUrl":null,"url":null,"abstract":"<p><p>Sjögren's disease is a systemic autoimmune disorder characterised by hyperactivation of B-cells and cytokine production. The condition may evolve from an asymptomatic, indolent course, with glandular involvement, to several extra-glandular systemic manifestations up to lymphoma development. Recent efforts have been undertaken to identify patient phenotypes at risk of developing specific extraglandular manifestations in order to improve patient management. A more detailed understanding and characterisation of pathogenetic mechanisms, operating during the course of the disease, may facilitate earlier diagnosis, enable subphenotyping of patients and suggest novel therapeutic modalities to address the unmet needs of the disease in the upcoming years. In this review, following the others of this series, we will summarise the most recent literature on Sjögren's disease pathogenesis and clinical features focusing in particular on new insights into Sjögren's disease molecular stratification and therapeutic advances in the era of precision medicine.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"2322-2335"},"PeriodicalIF":3.4000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.55563/clinexprheumatol/5xq3fb","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Sjögren's disease is a systemic autoimmune disorder characterised by hyperactivation of B-cells and cytokine production. The condition may evolve from an asymptomatic, indolent course, with glandular involvement, to several extra-glandular systemic manifestations up to lymphoma development. Recent efforts have been undertaken to identify patient phenotypes at risk of developing specific extraglandular manifestations in order to improve patient management. A more detailed understanding and characterisation of pathogenetic mechanisms, operating during the course of the disease, may facilitate earlier diagnosis, enable subphenotyping of patients and suggest novel therapeutic modalities to address the unmet needs of the disease in the upcoming years. In this review, following the others of this series, we will summarise the most recent literature on Sjögren's disease pathogenesis and clinical features focusing in particular on new insights into Sjögren's disease molecular stratification and therapeutic advances in the era of precision medicine.
斯约金氏病是一种全身性自身免疫性疾病,其特点是 B 细胞过度激活和细胞因子分泌过多。该病可从无症状、无症状、腺体受累发展为多种腺体外系统性表现,甚至发展为淋巴瘤。近年来,人们一直在努力确定有可能出现特定腺外表现的患者表型,以改善对患者的管理。更详细地了解和描述淋巴瘤发病过程中的致病机制,有助于更早地诊断淋巴瘤,对患者进行亚表型分析,并提出新的治疗方法,以满足未来几年淋巴瘤治疗的需要。在本综述中,我们将继本系列的其他综述之后,总结有关斯约戈伦病发病机制和临床特征的最新文献,尤其侧重于斯约戈伦病分子分层的新见解和精准医学时代的治疗进展。
期刊介绍:
Clinical and Experimental Rheumatology is a bi-monthly international peer-reviewed journal which has been covering all clinical, experimental and translational aspects of musculoskeletal, arthritic and connective tissue diseases since 1983.